| Completed | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphom NCT02213913 | University of Chicago | Phase 1 / Phase 2 |
| Completed | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Ce NCT01959477 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With NCT01815749 | City of Hope Medical Center | Phase 1 |
| Completed | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hemato NCT01789255 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas NCT01805037 | Northwestern University | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgki NCT01408043 | Case Comprehensive Cancer Center | N/A |
| Completed | Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple NCT02037256 | Barbara Ann Karmanos Cancer Institute | N/A |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers NCT01254578 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell NCT01239875 | Mayo Clinic | EARLY_Phase 1 |
| Completed | RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors NCT01158274 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma NCT01045928 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Completed | FAU in Treating Patients With Advanced Solid Tumors or Lymphoma NCT00769288 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be NCT00891072 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction NCT00499811 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, NCT00458731 | National Cancer Institute (NCI) | Phase 1 |
| Completed | PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00348985 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas NCT00096005 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymp NCT00101244 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas NCT00098891 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma NCT00089076 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction NCT00054483 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |